Drugs / GUB014295
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06144684 Comparator | Nov 2023 → Jan 2026 | obesity disorder | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GUB014295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06144684 ↗ |
| Route | Subcutaneous | “single subcutaneous dose is administered in part 1” NCT06144684 ↗ |